Novartis announced plans to build an integrated biomedical Research & Development center in Shanghai’s Zhangjiang Hi-Tech Park that will become an integral part of the Group’s global research and development network.
The Centers for Disease Control and Prevention (CDC) today launched a national public education and awareness campaign on Chronic Fatigue Syndrome (CFS), a weakening and often devastating illness for millions of Americans. The campaign, called “Get Informed. Get Diagnosed. Get Help”, is designed to increase awareness among clinicians and the public, because 80 percent of Americans afflicted with CFS illness may not know they have it.
Governor Mike Huckabee of Arkansas and Pfizer Inc today announced the formation of Balance It Out: Arkansas, a new school-based community program to reduce the number of children who are overweight or at risk of becoming overweight, effectively diminishing their risk of developing chronic illness. In December 2006, the program will begin in Little Rock, AR, with a health fair for state employees designed to increase awareness of health risk factors and steps to prevent disease. Beginning in early 2007, the program will reach children and their families in the Dollarway (Pine Bluff), Harrison and Paragould school districts.
Two leading players within the growing biofuels industry, Broin and Novozymes, announced a collaboration to take the next steps needed to bring cost-effective ethanol derived from corn stover to market. The collaboration is an extension of the close partnership between the two companies and is a great opportunity for Novozymes to put its unique biotechnology platform at work and for Broin to aim at a fast commercialization.
IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted an electronic New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Junovan(TM) (mifamurtide for injection), requesting approval for its use in the treatment of newly diagnosed resectable high grade osteosarcoma patients following surgical resection in combination with multiple agent chemotherapy.
Australian researchers have found that exposure to measured doses of ultraviolet light, such as sunlight, could reduce asthma. The research team at Perth’s Telethon Institute for Child Health Research, through funding provided by the Asthma Foundation of WA, studied the effect of ultraviolet light on the development of asthma-like symptoms in mice, such as inflamed airways and lungs.
On Tuesday and Wednesday of this week, over 150 community leaders and human service providers will come together to strengthen how vulnerable residents are readied for and helped during a disaster. Katrina?s Lesson: Reach Our Vulnerable Residents NOW is one of the first conferences of its kind in King County to unite private and public agencies in this effort.
Novartis (NYSE: NVS) announced today results of pivotal Phase III clinical trial data for its innovative cell culture-derived influenza vaccine demonstrating that it is highly capable of producing an immune response (“immunogenic”), one at least as strong as the traditional egg-derived influenza vaccine Aggripal? for each of the three influenza strains studied.
Merck KGaA and Glenmark Pharmaceuticals S.A (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL), have entered into an agreement for Glenmark?s DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes in Phase II of clinical development. The transaction is expected to close this year upon approval of the exclusive license to GRC 8200 by the U.S. anti-trust agencies under the HSR Act.
Case Western Reserve University’s Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a “first in class” drug that targets a specific DNA repair pathway.